CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02954874
Title field or adapter rule: {'original_value': 'A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:30.403638+00:00
Published At: 2026-10-26T00:00:00+00:00
Record Updated At: 2026-10-26
Source Retrieved At: 2026-10-31T22:18:22.973355+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Breast Carcinoma In Situ", "Invasive Breast Carcinoma", "Stage I Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-26", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT02954874"
protocolSection.identificationModule.officialTitle: "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With \u0026gt;/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Arm I (observation)', 'Arm II (pembrolizumab)'], 'description': 'Undergo collection of blood samples', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (observation)', 'Arm II (pembrolizumab)'], 'description': 'Correlative studies', 'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (observation)'], 'description': 'Undergo standard monitoring', 'name': 'Patient Observation', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm II (pembrolizumab)'], 'description': 'Given IV', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (observation)', 'Arm II (pembrolizumab)'], 'description': 'Ancillary studies', 'name': 'Quality-of-Life Assessment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (observation)', 'Arm II (pembrolizumab)'], 'description': 'Ancillary studies', 'name': 'Questionnaire Administration', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Arm I (observation)', 'Arm II (pembrolizumab)'], 'description': 'Undergo radiation therapy', 'name': 'Radiation Therapy', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.